All News
Filter News
Found 573,100 articles
-
Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products
10/18/2019
Concept Medical B.V. with its headquarters in Tampa, Florida has announced that on 16th October 2019, they have received the CE certification for their MagicTouch group of products.
-
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting
10/18/2019
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced an eAbstract presentation at ANESTHESIOLOGY® 2019, the Annual Meeting of the American Society of Anesthesiologists in Orlando, FL from October 19-23, 2019.
-
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
10/18/2019
Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy compared to vehicle
-
Nordic Nanovector ASA - Key Information Regarding Potential Repair Offering
10/18/2019
Reference is made to the announcement by Nordic Nanovector ASA on 18 October 2019 concerning a private placement with gross proceeds in the amount of NOK 242 525 624 and that the Company is considering to conduct a repair offering of up to 2,204,778 new shares with non-tradeable subscription rights to eligible shareholders.
-
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
10/18/2019
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the board, and several major investors.
-
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
10/18/2019
Arena Pharmaceuticals, Inc. will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate receptor modulator, in patients with moderately to severely active ulcerative colitis at the 25th Annual United European Gastroenterology Week.
-
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
10/18/2019
Isofol Medical AB, announced the successful completion of Japan's Pharmaceutical and Medical Devices Agency review of the Clinical Trial Notification, allowing the start of the pivotal Phase 3 AGENT clinical study in metastatic colorectal cancer at Japanese sites.
-
Getinge Q3 2019 Result: Continued Growth and Improved Margins
10/18/2019
We continue to show strong organic sales growth and improved margins in the third quarter", says Mattias Perjos, President & CEO at Getinge.
-
EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
10/18/2019
Amgen and UCB announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending Marketing Authorization for EVENITY® for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke.
-
The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds Promise as a New Treatment Option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)
10/18/2019
Xcovery Holdings, Inc. announced that ensartinib, the company’s lead drug candidate, demonstrated efficacy and safety in patients with crizotinib-refractory, anaplastic lymphoma kinase positive non-small cell lung cancer, including those with brain metastases.
-
Growth of Breast Cancer Therapeutics Market to be Impacted by the Rise in Strategic Collaborations | Technavio
10/18/2019
The market will accelerate at a CAGR of close to 8% between 2019 and 2023
-
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
10/18/2019
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a conditional marketing authorization for V920 Ebola Zaire vaccine If affirmed by the European Commission, the vaccine will be authorized under the brand name ERVEBO® and indicated for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease caused by Zaire Ebola virus.
-
Nordic Nanovector - Private Placement Successfully Completed - Oct. 18, 2019
10/18/2019
The Company announces that it has raised NOK 242,525,624 in gross proceeds through a private placement of 11,023,892 new shares The Private Placement was completed at a subscription price of NOK 22.00 per share, which was determined through an accelerated book-building process.
-
Globe Life Inc. Announces Third Quarter 2019 Earnings Release And Conference Call
10/18/2019
Globe Life Inc. will release Third Quarter 2019 earnings after the market closes on Wednesday, Oct. 23 2019.
-
Growth of MRI Systems Market to Be Impacted by the Software Advances in MRI Technology | Technavio
10/18/2019
The market will accelerate at a CAGR of over 5% between 2019-2023
-
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
10/18/2019
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V.
-
Growth of Proton Pump Inhibitors (PPIs) Market to Be Impacted by the Rising Prevalence of Obesity | Technavio
10/18/2019
The market will accelerate at a CAGR of over 4% between 2019-2023
-
Tampa General Hospital's New Diagnostic Center Offers Top-Notch Treatment for the Sun City Center Community
10/18/2019
Tampa General Hospital has opened a new 10,000-square-foot diagnostic center, located at 16521 U.S. 301 in Wimauma, that features an urgent care clinic, a primary care practice, diagnostic imaging and a laboratory..
-
For fiscal year 2019, the agency reported 1,171 generic drug approvals, 935 of them full approvals and 236 tentative approvals. This is up from last year’s all-time record of 971 generic drug approvals.
-
No matter where in the process you are, here are the questions you should be asking your interviewer.